Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Mimedx Group Inc's Business Segments
Mimedx Group Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Surgical
Total Revenue
$ 64
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Surgical0%
- Wound74.1%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Surgical | $ 76 | - |
| Wound | $ 48 | 74.1% |
Revenue by Product & Service Category - FY
- Surgical61.1%
- Wound38.9%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Surgical | $ 39 | 61.1% |
| Wound | $ 25 | 38.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Surgical0%
- Wound74.1%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Surgical | $ 76 | - |
| Wound | $ 48 | 74.1% |
Description of Mimedx Group Inc
MiMedx Group Inc is a leading biopharmaceutical company that develops and markets innovative regenerative biologics and biomaterial products. The company specializes in the research and development of advanced wound care products, tissue repair products, and human placental tissue-based products designed to promote healing and tissue regeneration.
Founded in 2008, MiMedx Group Inc is headquartered in Marietta, Georgia, USA, with additional operations in Europe and Asia. The company has grown to become a leading provider of advanced wound care products and regenerative biologics with its proprietary platform technology, Purion. These products are designed to provide a safe, effective, and cost-efficient solution to treat chronic wounds, surgical wounds, and other tissue injuries.
MiMedx's Purion platform technology allows for the creation of human placental tissue-based products that can be implanted to promote healing and tissue regeneration. The company's portfolio of products includes AmnioFix® and EpiFix® for advanced wound care and surgical applications, Purion® for tissue repair and regeneration, and OrthoFlo® for orthopedic applications.
AmnioFix® and EpiFix® are MiMedx's flagship products, which are derived from human amniotic membrane tissue. Both products are used to treat chronic and acute wounds, such as diabetic foot ulcers, pressure ulcers, venous leg ulcers, and surgical wounds. The products contain natural growth factors and other bioactive molecules that promote healing and tissue regeneration.
Purion® is a new line of tissue repair and regeneration products that is expected to drive future growth for MiMedx Group Inc. This technology platform allows the processing and sterilization of human tissue to produce purified extracellular matrix (ECM) that can be used to repair, regenerate, and remodel tissue defects, such as bone, cartilage, and soft tissue.
OrthoFlo® is MiMedx's newest product line that is designed to enhance the healing of orthopedic injuries and surgical procedures. This product is derived from human amniotic fluid and contains growth factors and other natural products that are beneficial for bone and tissue repair.
In addition to these products, MiMedx Group Inc also offers a range of training, education, and support services to healthcare professionals to ensure that their products are used effectively and safely. The company also works closely with healthcare providers to develop customized treatment plans and clinical protocols to ensure optimal patient outcomes.
MiMedx Group Inc is committed to advancing the field of regenerative medicine by developing and commercializing innovative products that improve patient outcomes, reduce healthcare costs, and enhance quality of life. With its proprietary technology platform and extensive product portfolio, MiMedx is well-positioned for continued growth and success in the years to come.
Founded in 2008, MiMedx Group Inc is headquartered in Marietta, Georgia, USA, with additional operations in Europe and Asia. The company has grown to become a leading provider of advanced wound care products and regenerative biologics with its proprietary platform technology, Purion. These products are designed to provide a safe, effective, and cost-efficient solution to treat chronic wounds, surgical wounds, and other tissue injuries.
MiMedx's Purion platform technology allows for the creation of human placental tissue-based products that can be implanted to promote healing and tissue regeneration. The company's portfolio of products includes AmnioFix® and EpiFix® for advanced wound care and surgical applications, Purion® for tissue repair and regeneration, and OrthoFlo® for orthopedic applications.
AmnioFix® and EpiFix® are MiMedx's flagship products, which are derived from human amniotic membrane tissue. Both products are used to treat chronic and acute wounds, such as diabetic foot ulcers, pressure ulcers, venous leg ulcers, and surgical wounds. The products contain natural growth factors and other bioactive molecules that promote healing and tissue regeneration.
Purion® is a new line of tissue repair and regeneration products that is expected to drive future growth for MiMedx Group Inc. This technology platform allows the processing and sterilization of human tissue to produce purified extracellular matrix (ECM) that can be used to repair, regenerate, and remodel tissue defects, such as bone, cartilage, and soft tissue.
OrthoFlo® is MiMedx's newest product line that is designed to enhance the healing of orthopedic injuries and surgical procedures. This product is derived from human amniotic fluid and contains growth factors and other natural products that are beneficial for bone and tissue repair.
In addition to these products, MiMedx Group Inc also offers a range of training, education, and support services to healthcare professionals to ensure that their products are used effectively and safely. The company also works closely with healthcare providers to develop customized treatment plans and clinical protocols to ensure optimal patient outcomes.
MiMedx Group Inc is committed to advancing the field of regenerative medicine by developing and commercializing innovative products that improve patient outcomes, reduce healthcare costs, and enhance quality of life. With its proprietary technology platform and extensive product portfolio, MiMedx is well-positioned for continued growth and success in the years to come.
MiMedx Group Inc. is a biopharmaceutical company recognized for its innovative approaches in the field of regenerative medicine and therapeutic biologics. The companys diverse portfolio directly addresses various segments of the healthcare industry, with a strong emphasis on healing, regeneration, and improving patient outcomes. An extensive overview of MiMedx Group Inc.s segments, products, and services includes the following:
1. Wound Care Segment
The Wound Care segment of MiMedx is dedicated to providing advanced solutions for chronic and complex wounds resulting from conditions like diabetes, venous leg ulcers, pressure ulcers, and more. The products in this segment are designed to enhance the natural healing process, minimize complications, and improve patient outcomes.
- EpiFix® Human Amniotic Membrane Allograft: This product is derived from donated human placental tissue and is used to facilitate healing in chronic and acute wounds. EpiFix® is characterized by its unique properties that support tissue regeneration and provide a natural barrier against infection.
- AmnioFix® Injectable: This injectable product is made from human amniotic tissue and is indicated for use in a variety of chronic pain and wound care applications. Its formulation aids in reducing inflammation and promoting healing at the injection site.
- EpiBurn® Dehydrated Human Amnion/Chorion Membrane (dHACM) Allograft: EpiBurn® is specially designed for use in burn treatment. It helps create a favorable environment for healing while protecting the wound from external contaminants.
Surgical & Sports Medicine Segment
This segment focuses on innovative solutions for soft tissue repair and regeneration that are crucial in surgical settings. The products cater to orthopedic surgeons and sports medicine specialists who require biologics to enhance recovery and treat injuries effectively.
- AmnioFix® Sports Med: Specifically designed for orthopedic applications, this allograft assists in the recovery of soft tissue repairs, providing a matrix for cellular migration and growth.
- Augment Regenerative Solutions: These solutions amplify the body’s own healing response and are used in various surgical procedures to enhance the regeneration of damaged tissues.
- HYALOFAST® Fast-Setting Scaffold: This product is a scaffold that provides a structural support matrix for tissue regeneration and is used in conjunction with surgical procedures to facilitate a faster healing response.
Orthopedics Segment
In the Orthopedics segment, MiMedx focuses on providing products that enhance healing following orthopedic procedures. The emphasis is on treatments that facilitate tissue regeneration and restore function effectively.
- OrthoFlo® Amniotic Fluid: This amniotic fluid product is designed to support soft tissue and bone healing, making it a critical component in various orthopedic surgeries.
- HydroFix® Ortho Shield: This product serves as a barrier to protect soft tissues and bone during and post-surgery, reducing the risk of damage and promoting optimal healing conditions.
Podiatry Segment
MiMedx caters to podiatrists with specialized products targeting foot and ankle conditions. This segment addresses the unique challenges presented by lower extremity wounds and other podiatric concerns.
- EpiFix® Human Amniotic Membrane Allograft: Similar to its application in the wound care segment, EpiFix® is used in podiatry to promote healing of chronic wounds on the feet, enhancing recovery rates for patients with diabetic foot ulcers and other conditions.
- AmnioFix® Injectable: Its use extends into the podiatry field where it aids in managing pain and inflammation in conditions affecting the foot and ankle.
Ophthalmology Segment
The Ophthalmology segment includes products that aim to improve ocular health, manage dry eye, reduce inflammation, and enhance overall visual comfort.
- MiSte®: This eye drop solution is designed for individuals with dry eye syndrome, offering lubrication and moisture to enhance visual function.
- Episil®: Used for its soothing properties, Episil® helps relieve allergic reactions and irritation, supporting patients eye health and comfort.
Conclusion
MiMedx Group Inc. stands at the forefront of regenerative medicine, leveraging its product portfolio to address critical healthcare needs across multiple segments. By focusing on innovative biologics, the company aims to provide effective solutions that not only enhance the healing process but also improve the quality of life for patients suffering from a variety of medical conditions. This comprehensive approach showcases MiMedxs commitment to advancing medical science and patient care.
,
1. Wound Care Segment
The Wound Care segment of MiMedx is dedicated to providing advanced solutions for chronic and complex wounds resulting from conditions like diabetes, venous leg ulcers, pressure ulcers, and more. The products in this segment are designed to enhance the natural healing process, minimize complications, and improve patient outcomes.
- EpiFix® Human Amniotic Membrane Allograft: This product is derived from donated human placental tissue and is used to facilitate healing in chronic and acute wounds. EpiFix® is characterized by its unique properties that support tissue regeneration and provide a natural barrier against infection.
- AmnioFix® Injectable: This injectable product is made from human amniotic tissue and is indicated for use in a variety of chronic pain and wound care applications. Its formulation aids in reducing inflammation and promoting healing at the injection site.
- EpiBurn® Dehydrated Human Amnion/Chorion Membrane (dHACM) Allograft: EpiBurn® is specially designed for use in burn treatment. It helps create a favorable environment for healing while protecting the wound from external contaminants.
Surgical & Sports Medicine Segment
This segment focuses on innovative solutions for soft tissue repair and regeneration that are crucial in surgical settings. The products cater to orthopedic surgeons and sports medicine specialists who require biologics to enhance recovery and treat injuries effectively.
- AmnioFix® Sports Med: Specifically designed for orthopedic applications, this allograft assists in the recovery of soft tissue repairs, providing a matrix for cellular migration and growth.
- Augment Regenerative Solutions: These solutions amplify the body’s own healing response and are used in various surgical procedures to enhance the regeneration of damaged tissues.
- HYALOFAST® Fast-Setting Scaffold: This product is a scaffold that provides a structural support matrix for tissue regeneration and is used in conjunction with surgical procedures to facilitate a faster healing response.
Orthopedics Segment
In the Orthopedics segment, MiMedx focuses on providing products that enhance healing following orthopedic procedures. The emphasis is on treatments that facilitate tissue regeneration and restore function effectively.
- OrthoFlo® Amniotic Fluid: This amniotic fluid product is designed to support soft tissue and bone healing, making it a critical component in various orthopedic surgeries.
- HydroFix® Ortho Shield: This product serves as a barrier to protect soft tissues and bone during and post-surgery, reducing the risk of damage and promoting optimal healing conditions.
Podiatry Segment
MiMedx caters to podiatrists with specialized products targeting foot and ankle conditions. This segment addresses the unique challenges presented by lower extremity wounds and other podiatric concerns.
- EpiFix® Human Amniotic Membrane Allograft: Similar to its application in the wound care segment, EpiFix® is used in podiatry to promote healing of chronic wounds on the feet, enhancing recovery rates for patients with diabetic foot ulcers and other conditions.
- AmnioFix® Injectable: Its use extends into the podiatry field where it aids in managing pain and inflammation in conditions affecting the foot and ankle.
Ophthalmology Segment
The Ophthalmology segment includes products that aim to improve ocular health, manage dry eye, reduce inflammation, and enhance overall visual comfort.
- MiSte®: This eye drop solution is designed for individuals with dry eye syndrome, offering lubrication and moisture to enhance visual function.
- Episil®: Used for its soothing properties, Episil® helps relieve allergic reactions and irritation, supporting patients eye health and comfort.
Conclusion
MiMedx Group Inc. stands at the forefront of regenerative medicine, leveraging its product portfolio to address critical healthcare needs across multiple segments. By focusing on innovative biologics, the company aims to provide effective solutions that not only enhance the healing process but also improve the quality of life for patients suffering from a variety of medical conditions. This comprehensive approach showcases MiMedxs commitment to advancing medical science and patient care.
,